Top Markets
Coin of the day
Evaxion Biotech A/S Evaxion Biotech A/S

Evaxion Biotech A/S

EVAX
Rang in aandelen #29740
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Aandeelprijs
$3.14
Laatst gesynchroniseerd: 2026-08-18
Marktkapitalisatie
$19.83M
Verandering (1 dag)
0.32%
Verandering (1 jaar)
3.29%
Land
DK
Handel Evaxion Biotech A/S (EVAX)

Categorie

Dividendrendementgeschiedenis voor Evaxion Biotech A/S (EVAX)
Het dividendrendement (TTM) van Evaxion Biotech A/S (aandelsymbool: EVAX) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Evaxion Biotech A/S (EVAX) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten